Cargando…
A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology
Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant role starting in the early phases of cancer progression. This event occurs in a three-dimensional (3D) environment, which to date, has been difficult to reproduce in vitro due to its complexity. While bi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509120/ https://www.ncbi.nlm.nih.gov/pubmed/31073193 http://dx.doi.org/10.1038/s41598-019-43613-9 |
_version_ | 1783417181402300416 |
---|---|
author | Candini, Olivia Grisendi, Giulia Foppiani, Elisabetta Manuela Brogli, Matteo Aramini, Beatrice Masciale, Valentina Spano, Carlotta Petrachi, Tiziana Veronesi, Elena Conte, Pierfranco Mari, Giorgio Dominici, Massimo |
author_facet | Candini, Olivia Grisendi, Giulia Foppiani, Elisabetta Manuela Brogli, Matteo Aramini, Beatrice Masciale, Valentina Spano, Carlotta Petrachi, Tiziana Veronesi, Elena Conte, Pierfranco Mari, Giorgio Dominici, Massimo |
author_sort | Candini, Olivia |
collection | PubMed |
description | Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant role starting in the early phases of cancer progression. This event occurs in a three-dimensional (3D) environment, which to date, has been difficult to reproduce in vitro due to its complexity. While bi-dimensional cultures have generated substantial data, there is a progressive awareness that 3D culture strategies may rapidly increase the understanding of tumor development and be used in anti-cancer compound screening and for predicting response to new drugs utilizing personalized approaches. However, simple systems capable of rapidly rebuilding cancer tissues ex-vivo in 3D are needed and could be used for a variety of applications. Therefore, we developed a flat, handheld and versatile 3D cell culture bioreactor that can be loaded with tumor and/or normal cells in combination which can be monitored using a variety of read-outs. This biocompatible device sustained 3D growth of tumor cell lines representative of various cancers, such as pancreatic and breast adenocarcinoma, sarcoma, and glioblastoma. The cells repopulated the thin matrix which was completely separated from the outer space by two gas-permeable membranes and was monitored in real-time using both microscopy and luminometry, even after transportation. The device was tested in 3D cytotoxicity assays to investigate the anti-cancer potential of chemotherapy, biologic agents, and cell-based therapy in co-cultures. The addition of luciferase in target cancer cells is suitable for comparative studies that may also involve parallel in vivo investigations. Notably, the system was challenged using primary tumor cells harvested from lung cancer patients as an innovative predictive functional assay for cancer responsiveness to checkpoint inhibitors, such as nivolumab. This bioreactor has several novel features in the 3D-culture field of research, representing a valid tool useful for cancer investigations, drug screenings, and other toxicology approaches. |
format | Online Article Text |
id | pubmed-6509120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65091202019-05-22 A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology Candini, Olivia Grisendi, Giulia Foppiani, Elisabetta Manuela Brogli, Matteo Aramini, Beatrice Masciale, Valentina Spano, Carlotta Petrachi, Tiziana Veronesi, Elena Conte, Pierfranco Mari, Giorgio Dominici, Massimo Sci Rep Article Tumors develop within complex cell-to-cell interactions, with accessory cells playing a relevant role starting in the early phases of cancer progression. This event occurs in a three-dimensional (3D) environment, which to date, has been difficult to reproduce in vitro due to its complexity. While bi-dimensional cultures have generated substantial data, there is a progressive awareness that 3D culture strategies may rapidly increase the understanding of tumor development and be used in anti-cancer compound screening and for predicting response to new drugs utilizing personalized approaches. However, simple systems capable of rapidly rebuilding cancer tissues ex-vivo in 3D are needed and could be used for a variety of applications. Therefore, we developed a flat, handheld and versatile 3D cell culture bioreactor that can be loaded with tumor and/or normal cells in combination which can be monitored using a variety of read-outs. This biocompatible device sustained 3D growth of tumor cell lines representative of various cancers, such as pancreatic and breast adenocarcinoma, sarcoma, and glioblastoma. The cells repopulated the thin matrix which was completely separated from the outer space by two gas-permeable membranes and was monitored in real-time using both microscopy and luminometry, even after transportation. The device was tested in 3D cytotoxicity assays to investigate the anti-cancer potential of chemotherapy, biologic agents, and cell-based therapy in co-cultures. The addition of luciferase in target cancer cells is suitable for comparative studies that may also involve parallel in vivo investigations. Notably, the system was challenged using primary tumor cells harvested from lung cancer patients as an innovative predictive functional assay for cancer responsiveness to checkpoint inhibitors, such as nivolumab. This bioreactor has several novel features in the 3D-culture field of research, representing a valid tool useful for cancer investigations, drug screenings, and other toxicology approaches. Nature Publishing Group UK 2019-05-09 /pmc/articles/PMC6509120/ /pubmed/31073193 http://dx.doi.org/10.1038/s41598-019-43613-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Candini, Olivia Grisendi, Giulia Foppiani, Elisabetta Manuela Brogli, Matteo Aramini, Beatrice Masciale, Valentina Spano, Carlotta Petrachi, Tiziana Veronesi, Elena Conte, Pierfranco Mari, Giorgio Dominici, Massimo A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
title | A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
title_full | A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
title_fullStr | A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
title_full_unstemmed | A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
title_short | A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology |
title_sort | novel 3d in vitro platform for pre-clinical investigations in drug testing, gene therapy, and immuno-oncology |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509120/ https://www.ncbi.nlm.nih.gov/pubmed/31073193 http://dx.doi.org/10.1038/s41598-019-43613-9 |
work_keys_str_mv | AT candiniolivia anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT grisendigiulia anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT foppianielisabettamanuela anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT broglimatteo anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT araminibeatrice anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT mascialevalentina anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT spanocarlotta anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT petrachitiziana anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT veronesielena anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT contepierfranco anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT marigiorgio anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT dominicimassimo anovel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT candiniolivia novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT grisendigiulia novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT foppianielisabettamanuela novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT broglimatteo novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT araminibeatrice novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT mascialevalentina novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT spanocarlotta novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT petrachitiziana novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT veronesielena novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT contepierfranco novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT marigiorgio novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology AT dominicimassimo novel3dinvitroplatformforpreclinicalinvestigationsindrugtestinggenetherapyandimmunooncology |